In 1991, Travis et al. proposed a new category of large cell neuroendocrine carcinoma LCNEC . 1 Some investigators reported poor prognosis of LCNEC patients, with
INTRODUCTION
The patient was discharged on the 14 th postoperative day. However, he complained of right-sided lumbago two months after lung resection . Although his serum CEA level decreased to 6.5 ng! ml after surgery, it elevated again . NSE and CYFRA levels were not re-examined .
Bone scintigram and spinal MRI revealed metastasis in the right sacroiliac joint. CT scan showed a brain metastasis, but he had no neurological symptoms. He received 30-Gy whole brain irradiation and 30-Gy radiotherapy for bone metastasis to relieve the pain . Although his pain was alleviated, the sacroiliac joint and brain metastases did not shrink. We planned chemotherapy, but his general condition rapidly worsened and he became cachectic. He died on September 20, 2002, on the 99 th postoperative day.
DISCUSSION
Dresler and co-workers reported an 18 5-year survival in stage I LCNEC patients. 4 Garc! a-Yuste and associates reported 33 for the same population, and stage II and IIIA patients lived no longer than 18 months. 8 There is no evidence that supports different effect of postoperative adjuvant therapy for LCNEC patients. Cooper and co-workers recommended lobectomy and lymph node dissection followed by adjuvant therapy. 7 Iyoda and associates studied 50 patients with LCNEC, 9 with large cell carcinoma with neuroendocrine differentiation, and 14 with large cell carcinoma with neuroendocrine mor- phology . 9 Eleven patients with LCNEC and 5 patients with large cell carcinoma with neuroendocrine morphology underwent adjuvant chemotherapy. They resulted in significantly higher overall survival than the remaining 57 patients who did not receive adjuvant chemotherapy . 9 However, as their study design was retrospective and the number of patients was small, adjuvant chemotherapy efficacy is still not proved. Mazi! res reported that in 10 LCNEC patients with metastasis receiving palliative platinum-etoposide chemotherapy the partial response rate was 20 . 10 Additional studies are necessary to determine the role of adjuvant treatment in LCNEC management.
Radiation is an effective modality in pulmonary small cell carcinoma management. However, there have been no reports describing radiotherapy efficacy in LCNEC patients. We used radiotherapy for the brain and sacroiliac joint metastases in the present case. Although sarcoiliac pain was alleviated, the metastatic lesions did not shrink.
In summary, we reported an aggressive progression case of pulmonary LCNEC. Prognosis and treatment efficacy in LCNEC patients remain controversial, and further investigation is needed. 
